This is, to our knowledge, the first report linking receptor palmitoylation and nanodomain partitioning to modified or biased responses of a class B GPCR in pancreatic beta cells, opening the door for future studies based on the direct manipulation of these processes to control GLP-1R action, with the potential to translate into more effective diabetes therapies. The gene discussed is GLP1R; the disease is diabetes mellitus.